Kornimate/medical-research-clean huggingface dataset:
the effect of music periodicity on interictal epileptiform discharges

Conditions: Rolandic Epilepsy; Benign Childhood Epilepsy With Centrotemporal Spikes; Epilepsy; Seizures

Summary: the purpose of this study is to determine if having children listen to the music of wolfgang amadeus mozart (sonata for two pianos in d major, k. 448) will lessen the amount of spike discharges on his/her electroencephalography (eeg). these spike discharges often occur during a 24 hour period in the eeg of a child with benign childhood epilepsy with centrotemporal spikes (bcects), or rolandic epilepsy. should there be a decrease in the amount of spike discharges after listening to mozart's music, this information may lead to new understanding and possible treatments for epilepsy.


Eligibility criteria:
inclusion criteria: * female or male with bcects clinical history, and at least one seizure, as defined by the international league against epilepsy. * eeg consistent with features of bcects: centrotemporal (rolandic) interictal spike discharges (isds) with otherwise normal background interictal eeg * screening neurological examination normal (by pi or other pediatric neurologist in the division of pediatric neurology at musc) * age 5-12 years, inclusive * on less than or equal to 2 anti-epileptic drugs (aed) \[range 0-2 aeds\] exclusion criteria: * currently taking clonazepam or other benzodiazepines * inability to complete 12 hour admission and comply with study protocol * prohibited therapy or activities during study period: use of computer or video games. viewing of video tapes will be prohibited due to potential effect of music in videos on underlying process of study. * due to the confounding factor of probably suppression of ieds after a clinical seizure, any subject experiencing a seizure of any duration 24 hours prior to beginning the study will be excluded from the study. * for any subject experiencing a seizure during the study, data analysis will cease from that point onward.

Keywords: rolandic epilepsy benign childhood epilepsy with centrotemporal spikes (bcects) epilepsy seizures music mozart beethoven
low carbohydrate diet - effect on plasma lipids and metabolic markers

Conditions: Overweight and Obesity; Type IIb Hyperlipidaemia; Hypercholesterolemia Aggravated

Summary: low carbohydrate diet may influence the plasma lipid levels.

fasting plasma lipids will be measured in healthy volunteer randomized to low carbohydrate diet or usual diet for a period

Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: any disease or use of prescriptional medication

Keywords: cardio vascular risk factors
a study to test the safety and effectiveness of mk-0974 (telcagepant) co-administered with ibuprofen or acetaminophen in patients with migraines with or without aura (mk-0974-046)

Conditions: Migraine

Summary: this study will test the safety and how effective telcagepant is when taken with ibuprofen or acetaminophen in participants with migraine with or without aura. the primary study hypothesis is that at least one drug combination is superior to telecagepant alone in the treatment of acute migraines.


Eligibility criteria:
inclusion criteria: * must be 18 years of age or older * history of migraine with or without aura for more than 1 year with 1-8 moderate or severe migraine attacks per month in the 2 months prior to starting in the study * willing to stay awake for at least 2 hours after taking study drug * able to read, understand and complete questionnaires and diaries exclusion criteria: * breast-feeding, pregnant, or plan to become pregnant during the study * not able to tell migraine attack from other headaches * older than 50 years of age at migraine onset * have more than 15 headache days per month or have taken medication for acute headache on more than 10 days per month in any of the 3 months before starting in the study * history of gastric or small intestinal surgery * history of heart attack, stroke, unstable angina, coronary artery bypass surgery or transient ischemic attack in the 3 months before starting in the study * currently participating or have participated in a study with in investigational compound or device in the last 30 days
cardiovascular disease risk of awareness

Conditions: Cardiovascular Diseases

Summary: the cardiovascular risk reduction program (cardiorep) aims to raise risk awareness and reduce risk factors.

while 1/3 of premature deaths in individuals under the age of 70 in the world occur due to cardiovascular diseases (who 2022), circulatory system diseases are at the forefront with 36.76% according to the health statistics of the ministry of health in our country. it is necessary to raise awareness and gain healthy lifestyle behaviors in the prevention of cardiovascular diseases. the cardiovascular risk reduction program (cardiorep) aims to raise risk awareness and reduce risk factors.

Eligibility criteria:
inclusion criteria: * not having been diagnosed with cardiovascular disease. * using a smartphone. * agree to use the google fit app. exclusion criteria:
evaluating the impact of incentives on clinical trial participation

Conditions: Hiv; Aging; Incentives

Summary: the objective of this study is to investigate the impact of incentives on clinical trial participation. 1) characterize key stakeholders' views on and assessment of incentives, 2) reach consensus among stakeholders on the factors to be considered when choosing incentives and their relative importance, 3) pilot test using vignettes for incentive decision making. we hypothesize that potential study participants make trade-offs regarding the characteristics of a research study when deciding whether to volunteer. this amendment is to document irb reliance between ucr and usf.


Eligibility criteria:
inclusion criteria: * people living with hiv * biomedical hiv researchers * irb members/bioethicists involved in hiv research exclusion criteria: * people under 18 years of age * people living outside of the united states * people who do not speak english

Keywords: hiv aging incentives
image characteristic and longitudinal follow up of 18f-pmpbb3 (apn-1607) pet for progressive supranuclear palsy

Conditions: Progressive Supranuclear Palsy

Summary: the study will enroll 20 psp and 8 normal subjects with complete neurological examination, 18f-pmpbb3 (apn-1607) pet and mri assessment. to explore: (1) whether 18f-pmpbb3 (apn-1607) can detect the 4r tau protein in the brain of psp patients; (2) whether 18f-pmpbb3 (apn-1607) can distinguish the clinical characteristics of psp; (3) whether the distribution of tau deposition is related to disease severity, progression, and prognosis.

progressive supranuclear palsy (psp), also known as steele-richardson-olszewski syndrome, has a similar incidence in men and women. the pathophysiology of psp is remaining unclear, but it is known to be related to the abnormal accumulation of 4r tau protein in the brain. recently, new generation of novel radiotracer 18f-pmpbb3 (apn-1607), which can be labeled with 4r phf-tau without significant off-target binding, has been successfully developed. the study will enroll 20 psp and 8 normal subjects with complete neurological examination, 18f-pmpbb3 (apn-1607) pet and mri assessment. to explore: (1) whether 18f-pmpbb3 (apn-1607) can detect the 4r tau protein in the brain of psp patients; (2) whether 18f-pmpbb3 (apn-1607) can distinguish the clinical characteristics of psp; (3) whether the distribution of tau deposition is related to disease severity, progression, and prognosis. the research results will help to understand the potential of 18f-pmpbb3 (apn-1607) as a biomarker for diagnosis and therapeutic assessment tool for progressive nuclear paralysis as well as other tau proteinopathy.

Eligibility criteria:
inclusion criteria: 1. written informed consent must be obtained before any assessment is performed. 2. patients fulfill the criteria of ninds-spsp clinical criteria for the diagnosis of psp "as possible" or "probably" psp, and healthy volunteer with no clinically relevant finding on physical examination at screening visit. 3. age range 20-90 years exclusion criteria: 1. implantation of metal devices including cardiac pacemaker, intravascular metal devices. 2. major systemic diseases including coronary arterial disease, heart failure, uremia, hepatic failure, prominent strokes, acute myocardial infarction, poorly controlled diabetes, previous head injury, intracranial operation, hypoxia, sepsis or severe infectious diseases 3. major psychiatric disorders, drug or alcohol abuse and major depression 4. pregnant women or breast- feeding women

Keywords: tauopathy progressive supranuclear palsy f-18 apn1607 pet f-18 pmpbb3 pet
characteristics of nondystrophic myotonias

Conditions: Nondystrophic Myotonias; Myotonia Congenita; Myotonic Disorders

Summary: nondystrophic myotonias (ndm) are muscle disorders caused by genetic abnormalities in certain muscle cell membrane proteins. individuals with ndm experience limited muscle relaxation, which causes pain, weakness, and impaired physical activity. the purpose of this study is to better characterize the clinical features and symptoms of ndm.

nondystrophic myotonias are muscle disorders caused by abnormal muscle cell membrane proteins that affect the control of muscle fiber contraction. these disorders are extremely rare, and little is known about how to best treat the various subtypes of ndm. the purpose of this study is to characterize the clinical features and symptoms of ndm as well as to pair this data with specific ndm subtypes. in turn, this may lead to the development of improved treatments. the study will also establish clinical endpoints for use in future studies. this multi-center observational study will involve both a cross-sectional data analysis and a prospective longitudinal analysis. participants will initially attend a one-day outpatient study visit. various baseline measurements will be collected, including demographics, medical history, and quality of life measures. blood samples will be taken to evaluate laboratory values and genetic factors. participants will undergo manual muscle testing (mmt), clinical myotonia assessments, and functional movement assessments. routine nerve conduction studies and electromyography (emg) will also be performed in order to test for the presence of myotonia in specific muscles. annual follow-up evaluations will occur 1 and 2 years following the first study visit.

Eligibility criteria:
inclusion criteria: * clinical symptoms or signs suggestive of myotonia * presence of myotonic potentials on electromyography (emg) * persistence of symptoms and signs after discontinuation of medications that produce myotonia; such medications include fibric acid derivatives, hydroxymethylglutaryl coa reductase inhibitors, chloroquine, and colchicine * absence of features suggestive of myotonic dystrophy, including ptosis, temporal wasting, mandibular weakness, cataracts occurring before age 50, and evidence of multisystem defects (cardiac conduction defects, hypogonadism) exclusion criteria: * any other neurologic condition that might affect the assessment of the study measurements

Keywords: myotonia paramyotonia congenita thomsen's disease
side effects of pulmonary hypertension medications

Conditions: Pulmonary Hypertension

Summary: the study seeks to analyze the patient reported effects of pulmonary hypertension medications and compare these with the side effects described on the package inserts. side effects for these ph medications have been described in the adult population, but have never been described in the pediatric population. this information can better improve patient care and be used to characterize the side effects resultant from these medications.

as part of standard of care, patients are routinely asked about any symptoms they might be experiencing. this study seeks to quantify these symptoms for research purposes. participants will be identified through those who attend the pediatric pulmonary hypertension clinic at lpch. only children who are currently on one of seven ph medications (bosentan, epoprostenol, letairis, sildenafil, tadalafil, treprostinil, ventaris) will be approached. patients who consent to be in the study will answer a brief series of questions pertaining to the presence and duration of their symptoms. these will be correlated to a list of side effects taken from lexicomp (a medication database).

Eligibility criteria:
inclusion criteria: * pulmonary hypertension * currently taking at least one of the following ph medications (bosentan, epoprostenol, letairis, sildenafil, tadalafil, treprostinil, ventaris) exclusion criteria: * \>18 years
pegaptanib sodium compared to sham injection in patients with dme involving the center of the macula

Conditions: Diabetic Macular Edema

Summary: the purpose of the study is to determine whether pegaptanib sodium (macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections. a total of 176 patients will be enrolled


Eligibility criteria:
inclusion criteria: patients with clinically significant dme, va 20/50-20/320 in the study eye and 20/100 in the fellow eye
asparagus capsule consumption and blood sugar and lipids and oxidative stress

Conditions: Asparagus Capsule Consumption

Summary: participants were 44 overweight and obese persons, male and female, age 18-59 years. participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. they received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels.

the study design was cross-sectional. participants were 44 overweight and obese persons, male and female, age 18-59 years. participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. they received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels. analysis of covariance was used to analyze parameters between groups and paired t-test was used to analyze parameters intra-group.

Eligibility criteria:
inclusion criteria: * man or woman, aged between 18 to 59 years * body mass index more than 23 (asian criteria) * no history of hypertension, diabetes, cardiovascular disease, respiratory disease, endocrine disease, neuromuscular disease, musculoskeletal disease, liver disease, renal disease, immune disease, infectious disease, or cancer * no regular intake of dietary supplements, i.e., vitamins, antioxidants * no regular smokers or alcohol drinkers (\>2 times per week) * not sportman or regular exerciser (\>2 times per week or \>150 min per week) * no food allergy, especially shoot exclusion criteria: - current signs or symptoms of infection, i.e., fever, hyperpnea, dyspnea, and palpitations.
combination chemotherapy in treating patients with advanced solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase i trial to study the effectiveness of combination chemotherapy in treating patients who have advanced solid tumors.

objectives: i. determine the maximum tolerated dose of docetaxel administered in combination with cisplatin, fluorouracil, and leucovorin calcium in patients with advanced solid tumors. ii. determine the toxicities associated with this combination regimen in this patient population. iii. evaluate the clinical response to this combination regimen in these patients. outline: this is a dose escalation study of docetaxel and fluorouracil (5-fu). patients receive docetaxel iv over 1 hour on day 1, cisplatin iv over 1 hour on day 2, and leucovorin calcium iv immediately followed by 5-fu iv on days 1-5. treatment repeats every 3 weeks in the absence of disease progression. cohorts of 3-5 patients receive escalating doses of docetaxel and 5-fu until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which more than 1 of 3 or 1 of 5 patients experience dose limiting toxicity. patients are followed every 3 months until death. projected accrual: a total of 30 patients will be accrued for this study over 2 years.

Eligibility criteria:
disease characteristics: diagnosis of advanced solid tumor no lymphomas measurable disease patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: not specified hematopoietic: neutrophil count at least 1,000/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than upper limit of normal (uln) and sgot no greater than 2.5 times uln and alkaline phosphatase no greater than uln or sgot no greater than uln and alkaline phosphatase no greater than 5 times uln renal: creatinine no greater than 2.0 mg/dl other: no pre-existing peripheral neuropathy greater than grade 2 not pregnant or nursing fertile patients must use effective contraception prior concurrent therapy: no more than 2 prior treatments for metastatic disease biologic therapy: not specified chemotherapy: no prior high dose (pre transplant) chemotherapy prior paclitaxel allowed endocrine therapy: not specified radiotherapy: no prior pelvic radiotherapy surgery: not specified

Keywords: unspecified adult solid tumor, protocol specific
clinical outcome of neonates with gbs positive culture-12 year retrospective study

Conditions: Infants With Positive GBS Bacteremia

Summary: streptococci group b (gbs) is a the major reason for morbidity and mortality in neonates. it can present as pneumonia ,meningitis or sepsis.the mortality today is 5-20% and even more in preterm babies. during the past two decade, the introduction of protocols for prophylactic antibiotics for women with a high risk for gbs infection, have led to a decline of 65% in gbs cases(0.32 for 1000 live birth compared to 1.8 cases in 1000).the purpose of the study is to check the morbidity and mortality at sheba medical center in the last 12 years in children with positive blood culture for gbs. we assume that in our hospital the morbidity and mortality is less then expected. if proven right, we would then check the reasons for that outcome considering the type and length of treatment and the different virulence of the streptococcus.

this is a retrospective case control study. we will review from archive the charts of all the neonates with positive blood culture for gbs, reviewing the course and severity of their illness.

Eligibility criteria:
inclusion criteria: * gbs positive blood culture neonate and preterm babies exclusion criteria: * congenital malformations

Keywords: group b streptococci virulent morbidity mortality
nasopharyngeal carriage of s. pneumoniae

Conditions: Nasopharyngeal Carriage; Children, Only; Antibiotic Resistant Strain

Summary: this nasopharyngeal (np) carriage surveillance study was requested by the european agency for the evaluation of medicinal products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines (pcvs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of streptococcus pneumoniae serotypes in children with acute otitis media and modified the resistance of this bacterial species to antibiotics.

since september 2001, 121 pediatricians who are part of a research and teaching network (activ) throughout france participated at this prospective study. from october to june of each subsequent year, children of both sexes suffering from suppurative acute otitis media (aom) with fever and/or otalgia (in order to increase the probability of pneumococcal aom), aged 6 to 24 months, were enrolled. and a second group of healthy children aged 6 months to 15 years were also enrolled for the main study. for ancillary study a subgroup of children were enrolled for assessment of e. coli (esbl) resistance.

Eligibility criteria:
inclusion criteria: * both sexes * suffering from suppurative aom * age: 6 months to 24 months for aom * age: 6 months to 15 years for healthy children * informed consent from parents or guardians exclusion criteria: * children with antibiotic treatment within 7 days before enrolment, * severe underlying disease, * inclusion in the study during the previous 12 months

Keywords: pneumococcal conjugate vaccine streptococcus pneumoniae carriage
role of platelet rich plasma in enhancing graft take in chronic venous ulcers

Conditions: Chronic Venous Hypertension With Ulcer and Inflammation; Chronic Ulcer of Leg or Foot

Summary: chronic venous ulcers are considered a problem with a big morbidity impact on both the health facilities and patients, skin-grafting have shown not so perfect outcomes with such ulcers. in this study, the investigators compare combining autologous platelet rich plasma treatments with partial skin grafting in chronic ulcers, the results were compared to using only partial skin grafting, and among various types of chronic resistant ulcers.

fourteen patients had bilateral lower limb ulcers, and 6 of them had single large ulcers as follows; fourteen patients with chronic venous ulcers (12 of which had bilateral ulcers, 2 had single large ulcers) four patients, each with a single chronic post-traumatic ulcer two patients with bilateral chronic lymphatic ulcers. after detailed history, physical examination and investigations (such as duplex), * each patient with bilateral ulcers included in the study (14 patients) received treatment a on one ulcer and treatment b on the other ulcer. * in case of patients with single large ulcers (6 patients), treatment a was done on one half of the ulcer and treatment b on the other half of the ulcer (done in ulcers with an area greater than 10 x 10 cms). * treatment a included pre-operative intra-lesional prp injections in 1-week intervals for 3 times, followed by intra-operative intra-lesional injection of prp prior to meshed graft placement. prp was injected into the ulcer bed and ulcer edges using a sterile syringe. treatment b included only placement of meshed graft, with no prp treatment. * pre-operative preparation: ulcers were prepared by proper dressings and followed up until acquiring a clean bed. debridement was done as needed to obtain clean base ready for graft placement. * prp preparation: * 10 ml of blood was drawn from each patient intra operatively (autologous prp). * blood was collected in sterile tubes, anticoagulant citrate dextrose (acd) was used for anticoagulation, which is the same substance used to preserve viable platelets in blood banks for platelet transfer. * tubes were centrifuged in beckman allerga x-12 centrifuge for 20 mins, 3000 rpm. * each 10 ml of blood yielded an average of 3-4 ml of prp. calcium gluconate was added in a ratio of 1:10 to prp. post-operative assessment was carried out by follow up clinical examination, photography and weekly biopsy samples.

Eligibility criteria:
inclusion criteria: * patients with chronic ulcers for at least 6 months. * age ≧ 12 years. exclusion criteria: * patients younger than 12 years of age. * patients with diabetes or other diseases affecting tissue healing. * patients with current ongoing pathologies in arterial or venous systems. * patients with malignant ulcers. * patients on corticosteroids or other drugs affecting tissue healing. * patients with unrealistic expectations.

Keywords: chronic leg ulcers, prp split-thickness skin graft platelet-rich plasma